Christian Antoni

Dr. Christian Antoni has spent more than two decades committed to driving innovation in drug development for patients. Over the course of his career, he has led drug development functions at LEO Pharma, Sanofi, Novartis, and Schering Plough, with a focus on immunology and inflammatory disease.

Prior to joining industry, he established and led the clinical trial unit at Friedrich-Alexander University and was the lead investigator on all rheumatology development programs, including the first IIS trial that led to the psoriatic arthritis indication for the first TNF-alpha inhibitor, Remicade® (infliximab).

Christian completed his medical training and residency in internal medicine and rheumatology at Friedrich Alexander University, Germany, and is a member of the American College of Rheumatology (ACR) and the German Society of Rheumatology (DGRh).